D R Horton Inc vs Cassava Sciences Inc — how do they compare? D R Horton Inc trades at $151.45 (market cap $42.18B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: D R Horton Inc is far larger — about 883.4× Cassava Sciences Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| DHI | FLNA | |
|---|---|---|
Market Cap | $42.18B | $47.75M |
Sector | Consumer Cyclical | Health |
52-Week High | $184.04 | $4.64 |
52-Week Low | $132.53 | $0.87 |
Enterprise Value | $47.28B | -$34.93M |
Dividend Yield | 1.19% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Trailing returns across standard periods
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →